

09/608, 892

(FILE 'HOME' ENTERED AT 12:35:33 ON 15 MAY 2002)

FILE 'REGISTRY' ENTERED AT 12:35:47 ON 15 MAY 2002

L1 1 S GDYVS/SQEP

FILE 'CAPLUS' ENTERED AT 12:36:50 ON 15 MAY 2002

L2 1 S L1

FILE 'REGISTRY' ENTERED AT 12:37:23 ON 15 MAY 2002

L3 1 S ETVNF/SQEP

FILE 'CAPLUS' ENTERED AT 12:37:49 ON 15 MAY 2002

L4 1 S L3

FILE 'REGISTRY' ENTERED AT 12:38:32 ON 15 MAY 2002

L5 0 S (124219-00-7P OR 148719-50-0P OR 169249-03-0P OR 174641-93-1P

L6 10 S (124219-00-7 OR 148719-50-0 OR 169249-03-0 OR 174641-93-1 OR

FILE 'CAPLUS, USPATFULL' ENTERED AT 12:40:49 ON 15 MAY 2002

L7 51 S L6

FILE 'REGISTRY' ENTERED AT 12:41:39 ON 15 MAY 2002

FILE 'REGISTRY' ENTERED AT 12:42:19 ON 15 MAY 2002

L8 1 S (124219-00-7)/RN

=>

L7 ANSWER 51 OF 51 USPATFULL  
AN 90:7741 USPATFULL  
TI Biologically active peptides which inhibit toxoplasma multiplication  
IN Suzuki, Naoyoshi, Tokyo, Japan  
Osaki, Humio, Kobe, Japan  
PA Nippon Mining Co., Ltd., Tokyo, Japan (non-U.S. corporation)  
PI US 4897463 19900130  
AI US 1988-291039 19881228 (7)  
PRAI JP 1987-330142 19871228  
DT Utility  
FS Granted  
LN.CNT 578  
INCL INCLM: 530/329.000  
INCLS: 530/330.000  
NCL NCLM: 530/329.000  
NCLS: 530/330.000  
IC [4]  
ICM: C07K007-06  
EXF 530/329; 530/330; 514/17  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 51 hitrn

L7 ANSWER 51 OF 51 USPATFULL  
IT 124219-00-7P *see 85*  
(prepn. of, as immunoregulator for combating toxoplasma)

L8 1 (124219-00-7)/RN

=> d seq3

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

SEQ3 1 Asp-Asp-Asp-Asp-Asp

L10 ANSWER 4 OF 4 USPATFULL  
 AN 95:99132 USPATFULL  
 TI Physiologically active peptide having immunoregulatory activities  
 IN Suzuki, Naoyoshi, Tokyo, Japan  
 PA Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)  
 PI US 5464819 19951107  
 AI US 1991-729353 19910712 (7)  
 PRAI JP 1990-182714 19900712  
 DT Utility  
 FS Granted  
 LN.CNT 1134  
 INCL INCLM: 514/016.000  
 INCLS: 514/017.000; 514/018.000; 514/019.000; 530/329.000; 530/330.000;  
 530/331.000  
 NCL NCLM: 514/016.000  
 NCLS: 514/017.000; 514/018.000; 514/019.000; 530/329.000; 530/330.000;  
 530/331.000  
 IC [6]  
 ICM: A61K038-00  
 ICS: C07K005-00; C07K007-00; C07K017-00  
 EXF 514/16; 514/17; 514/18; 514/19; 530/329; 530/330; 530/331  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d kwic

L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS  
 AB . . . or inhibit prodn. of cellular proteins. Many of the peptides of  
 the invention may be produced in large quantity by **recombinant**  
 techniques and formulated in culture medium to produce the desired effect  
 on cultured cells and tissues. Certain of the libraries of the invention  
 and the peptides identified in them are particularly useful in  
 concatamer-based **recombinant** expression methods.  
 IT 124219-00-7P 148719-50-0P 169249-03-0P  
 174641-93-1P 204197-97-7P 211629-12-8P  
 273397-53-8P 387819-90-1P 387819-91-2P  
 387819-92-3P 387819-93-4P 387819-94-5P 387819-95-6P  
 387819-96-7P 387819-97-8P 387819-98-9P 387819-99-0P 387820-00-0P  
 387820-01-1P 387820-02-2P 387820-03-3P 387820-04-4P 387820-05-5P  
 387820-06-6P 387820-07-7P 387820-08-8P 387820-09-9P 387820-10-2P  
 387820-11-3P 387820-12-4P 387820-13-5P 387820-14-6P 387820-15-7P  
 387820-16-8P 387820-17-9P 387820-18-0P 387820-19-1P 387820-20-4P  
 387820-21-5P 387820-22-6P 387820-23-7P 387820-24-8P 387820-25-9P  
 387820-26-0P 387820-27-1P 387820-28-2P 387820-29-3P 387820-30-6P  
 387820-31-7P 387820-32-8P 387820-33-9P 387820-34-0P 387820-35-1P  
 387820-36-2P 387820-37-3P 387820-38-4P 387820-39-5P 387820-40-8P  
 387820-41-9P 387820-42-0P 387820-43-1P 387820-44-2P 387820-45-3P  
 387820-46-4P 387820-47-5P 387820-48-6P 387820-49-7P 387820-50-0P  
 387820-51-1P 387820-52-2P 387820-53-3P 387820-54-4P 387820-55-5P  
 387820-56-6P 387820-57-7P 387820-58-8P 387820-59-9P 387820-60-2P  
 387820-61-3P 387820-62-4P 387820-63-5P 387820-64-6P 387820-65-7P  
 387820-66-8P 387820-67-9P 387820-68-0P 387820-69-1P 387820-70-4P  
 387820-71-5P 387820-72-6P 387820-73-7P 387820-74-8P 387820-75-9P  
 387820-76-0P  
 RL: BUU (Biological use, unclassified); CPN (Combinatorial preparation);  
 PRP (Properties); BIOL (Biological study); CMBI (Combinatorial study);  
 PREP (Preparation); USES (Uses)  
 (protein sequence; synthesis of peptide libraries for use in culture  
 media)

=>

L5 ANSWER 4 OF 4 USPATFULL  
AN 95:99132 USPATFULL  
TI Physiologically active peptide having immunoregulatory activities  
IN Suzuki, Naoyoshi, Tokyo, Japan  
PA Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)  
PI US 5464819 19951107  
AI US 1991-729353 19910712 (7)  
PRAI JP 1990-182714 19900712  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Warden, Jill; Assistant Examiner: Huff, Sheela J.  
LREP Birch, Stewart, Kolasch & Birch  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)  
LN.CNT 1134  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
DETD Further, if desired, the physiologically active peptide of the present invention can also be produced by a **recombinant** DNA technique, utilizing a DNA coding for each peptide in combination with an appropriate host vector system.  
IT 57738-22-4 124218-98-0 124218-99-1 124219-00-7  
(immunoregulating compns. contg.)

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN 124219-00-7 REGISTRY

SEQ3 1 Asp-Asp-Asp-Asp-Asp

=>